Use of a Combined Preparation Gamalate B6 in the Functional and Organic Diseases of the Nervous System in Children and Adults (Review of the Literature and Our Own Observations)

S.K. Yevtushenko, D.A. Filimonov, O.S. Yevtushenko, I.S. Yevtushenko, Ye.A. Savchenko, A.V. Morozova

Abstract


At the present time, functional disorders in various organic diseases of the nervous system: anxiety, latent depression, cognitive impairment, insomnia, etc. — become increasingly important. These circumstances demanded a revision of the existing routine schemes of pharmacotherapy for neuropsychiatric disorders in children and adults. The review analyzes the possibility of applying the combined GABAergic preparation Gamalate B6 from a position of influence on the primary neurosis-like disorders, as well as on the similar conditions occurred in organic diseases of the nervous system of various etiologies. The results of the 3-year experience of using Gamalate B6 in adults in diseases, such as tension headaches, the effects of stroke, multiple sclerosis, are presented. Emphasis is placed on the application of the drug in neuropediatric practice (cerebral palsy in children, attention deficit disorder). The efficacy and safety of long-term course use of the drug in the treatment of functional and organic diseases of the nervous system in children and adults were proved.


Keywords


Gamalate B6; anxiety disorder; tension headache; effects of stroke; multiple sclerosis; cerebral palsy in children; attention deficit hyperactivity disorder

References


Дамбилова С.А. Биомаркеры церебральной ишемии / Дамбилова С.А., Скоромец А.А., Скоромец А.П. — СПб., 2013. — 334 с.

Евтушенко О.С. [и др.]. Шкалы в общей и детской неврологии / О.С. Евтушенко, Н.В. Яновская, О.Ю. Сухоносова, А.А. Омельяненко, Е.М. Фомичева [и др.]; Под ред. С.К. Евтушенко. — К.: Издатель Заславский А.Ю., 2015. — 104 c.

Евтушенко С.К. Сочетанная противосудорожная и иммуномодулирующая терапия труднокурабельных форм эпилепсии у детей // Вестник эпилептологии. — 2013. — № 2. — C. 45-54.

Завалишин И.А. Основные аспекты патогенеза рассеянного склероза // Рассеянный склероз. Клиническое руководство. — М., 2011. — С. 43-72.

Зыков В.П. Диагностика и лечение заболеваний нервной системы у детей / Под ред. В.П. Зыкова. — М., 2013. — 432 с.

Мищенко Т.С. Эффективность лечения мозгового инсульта в остром периоде // Новости медицины и фармации. — 2013. — № 449 (5). — C. 56-59.

Труфанов Е.А. Начальные клинические проявления болезни Паркинсона (клиника, параклинические исследования) // Международный неврологический журнал. — 2012. — № 5. — С. 75-80.

Пизова Н.В. Заболевания сердца и инсульты у лиц молодого возраста // Неврология, нейропсихиатрия, психосоматика. — 2014. — № 2. — C. 62-69.

ElAli A. [et al.]. Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation // Acta neuropathologica communications. — 2013. — № 1 (1). — Р. 75.

Everson-Rose S. [et al.]. Chronic Stress, Depressive Symptoms, Anger, Hostility, and Risk of Stroke and Transient Ischemic Attack in the Multi-Ethnic Study of Atherosclerosis // Stroke. — 2014.

Fioravanti M. [et al.]. A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline // BMJ open. — 2014. — № 7 (4). — Р. e005090.

McCully K.S. Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation // Ann. Clin. Lab. Sci. — 2009. — № 3 (39). — Р. 219-232.

Aneja S., Sharma S. Newer anti-epileptic drugs // Indian Pediatrics. — 2013. — V. 50, № 11. — Р. 1033-1040.

Anthierens S. [et al.]. Barriers to nonpharmacologic treatments for stress, anxiety, and insomnia: Family physicians’ attitudes toward benzodiazepine prescribing // Canadian Family Physician. — 2010. — № 11 (56).

Banfi S. [et al.]. Cyclic GABA-GABOB analogues. IV. Acti-vity on learning and memory // Il Farmaco; edizione scientifica. — 1984. — № 1 (39). — Р. 16-22.

Chen J.J., Marsh L. Anxiety in Parkinson’s disease: identification and management // Therapeutic advances in neurological disorders. — 2014. — № 1 (7). — Р. 52-9.

Cryan J.F., Kaupmann K. Don’t worry «B» happy!: A role for GABA B receptors in anxiety and depression // Trends in Pharmacological Sciences. — 2005. — V. 26, № 1. — Р. 36-43.

Cunha C., Monfils M.-H., Ledoux J.E. GABA(C) Receptors in the Lateral Amygdala: A Possible Novel Target for the Treatment of Fear and Anxiety Disorders? // Frontiers in behavioral neuroscience. — 2010. — 4. — Р. 6.

Dodge N.N. Cerebral Palsy: Medical Aspects // Pediatric Clinics of North America. — 2008. — V. 55, № 5. — Р. 1189-1207.

Gafford G.M. [et al.]. Cell-type specific deletion of GABA(A) 1 in corticotropin-releasing factor-containing neurons enhances anxiety and disrupts fear extinction // Proceedings of the National Academy of Sciences. — 2012. — V. 109, № 40. — Р. 16330-16335.

Garattini S. Glutamic acid, twenty years later // J. Nutr. — 2000. — № 4S, Suppl. (130). — Р. 901S-9S.

Johansen J.P. Neuroscience: anxiety is the sum of its parts // Nature. — 2013. — № 7444 (496). — Р. 174-5.

Kalueff A.V., Nutt D.J. Role of GABA in anxiety and depression // Depression and Anxiety. — 2007. — V. 24, № 7. — Р. 495-517.

Kane R.L. [et al.]. Visual Analog Scale pain reporting was standardized // Journal of Clinical Epidemiology. — 2005. — № 6 (58). — Р. 618-623.

Kessler R.C. [et al.]. Epidemiology of anxiety disorders // Current Topics in Behavioral Neurosciences. — 2010. — № 2 (2010). — Р. 21-35.

Krigger K.W. Cerebral palsy: An overview // American Family Physician. — 2006. — V. 73, № 1. — Р. 91-100.

Lydiard R.B. The role of GABA in anxiety disorders // The Journal of clinical psychiatry. — 2003. — 64, Suppl. 3. — Р. 21-27.

Meldrum B.S. Glutamate as a neurotransmitter in the brain: review of physiology and pathology // The Journal of nutrition. — 2000. — № 4S, Suppl. 130. — Р. 1007S-15S.

Möhler H. The GABA system in anxiety and depression and its therapeutic potential. — 2012. — Р. 42–53.

Novell R. [et al.]. Treatment of behavioral disorders in children with mild and moderate mental deficiency: Efficacy and safety of gamalate B6 // Psiquis Revista de Psiquiatria Psicologia Medica y Psicosomatica. — 1998. — 19 (7). — Р. S.

Ocañez K.L.S., McHugh R.K., W. Otto M. A meta-analytic review of the association between anxiety sensitivity and pain // Depression and Anxiety. — 2010. — № 8 (27). — Р. 760-767.

Olatunji B.O., Cisler J.M., Tolin D.F. Quality of life in the anxiety disorders: A meta-analytic review // Clinical Psychology Review. — 2007. — V. 27, № 5. — Р. 572-581.

Pellegata R. [et al.]. Cyclic GABA-GABOB analogues. III — Synthesis and biochemical activity of new alkyl and acyl derivatives of 4-hydroxy-2-pyrrolidinone // Il Farmaco; edizione scientifica. — 1981. — № 10 (36). — Р. 845-855.

Roy-Byrne P.P. The GABA-benzodiazepine receptor complex: structure, function, and role in anxiety // The Journal of clinical psychiatry. — 2005. — 66, Suppl. 2. — Р. 14-20.

Rudolph U., Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABA(A) receptor subtypes // Nature reviews. Drug discovery. — 2011. — № 9 (10). — Р. 685-697.

Sanders S., Shekhar A. Regulation of anxiety by GABA A receptors in the rat amygdala // Pharmacology Biochemistry and Behavior. — 1995. — № 4 (52). — Р. 701-706.

Sarup A., Larsson O.M., Schousboe A. GABA transporters and GABA-transaminase as drug targets // Current drug targets. CNS and neurological disorders. — 2003. — № 4 (2). — Р. 269-277.

Smith M.B. Methods of Non-α-Amino Acid Synthesis, Second Edition / M.B. Smith. — CRC Press. — 2013. — 242 р.

Straub K., Obrzut J.E. Effects of cerebral palsy on neuropsychological function // Journal of Developmental and Physical Disabilities. — 2009. — № 2 (21). — Р. 153-167.

Wong C.G.T., Bottiglieri T., Snead O.C. GABA, gamma-hydroxybutyric acid, and neurological disease // Annals of neuro-logy. — 2003. — 54, Suppl. 6. — Р. S3-S12.

Yamanaka A., Tsunematsu T. New approaches for the study of orexin function // Journal of Neuroendocrinology. — 2010. — V. 22, № 7. — Р. 818-824.




DOI: https://doi.org/10.22141/2224-0713.5.75.2015.78011

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru